Accelerating sales of Merck KGaA’s oral multiple sclerosis therapy Mavenclad helped the company to a double-digit rise in healthcare sales in the third quarter, and a rise in its full-year ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Mavenclad hasn’t really got going yet in sales terms, bringing in a modest €90 million in 2018 from the 50 or so countries it has been approved in to date, albeit up from just €5 million in ...

Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...

On an organic basis, sales rose across segments. Healthcare sales rose 6.2%, driven by high demand for Merck’s main ...

US pharma group Merck said the UAE Ministry of Health and Prevention has approved the registration of its Mavenclad (cladribine tablets) for the treatment of adult patients with highly active ...

Its health care business showed good profitability thanks to multiple sclerosis drug Mavenclad and cancer drug Erbitux, as ...

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

Blair’s MS is currently in remission. She exclusively told Us Weekly in August that she’s had “amazing” results with the medication Mavenclad. “It helped my movement and speech so much ...

Investing.com -- Shares of Merck KGaA surged after the company confirmed its outlook for fiscal year 2024 and revisions to its mid-term sales projections, particularly for its Life Science and ...